ArticleInternational journal of urology : official journal of the Japanese Urological Association2026
Perioperative Safety and Long-Term Oncological Outcomes of En Bloc Resection of Bladder Tumor: A Multicenter Real-World Study of 668 Patients.
Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate perioperative safety, pathological outcomes, and oncological outcomes of en bloc resection of bladder tumor (ERBT) in a large multicenter real-world cohort.
methodsWe retrospectively analyzed 668 patients who underwent ERBT at five institutions. Perioperative and pathological outcomes were assessed in the overall cohort. Recurrence-free survival (RFS) was evaluated in patients with pathologically confirmed non-muscle-invasive bladder cancer (NMIBC) without a history of upper tract urothelial carcinoma (n = 551). Clinicopathological prognosticators of recurrence were identified using Cox proportional hazards regression.
resultsThe median age was 73 years, and the median maximum tumor diameter was 15 mm. The median operative time and postoperative catheterization period were 48 min and 3 days, respectively. Perioperative complications occurred in 60 patients (9.0%), including eight (1.2%) with Clavien-Dindo Grade III or higher complications. Detrusor muscle was identified in 77.2% of evaluable specimens. Final pathology showed pTa, pT1, pTis, and pT2 disease in 377 (56.4%), 239 (35.8%), 16 (2.4%), and 25 patients (3.7%), respectively. With a median follow-up of 42 months, the estimated 1-, 2-, and 5-year RFS rates were 80.9%, 73.2%, and 57.1%, respectively. RFS did not differ significantly between pTa and pT1 disease (log-rank p = 0.39). Patients presenting with recurrent tumors had a significantly higher risk of subsequent intravesical recurrence than those with primary tumors (HR 2.06, 95% CI 1.38-3.07; p < 0.001).
conclusionsERBT demonstrated favorable perioperative safety and acceptable oncological outcomes in this large multicenter cohort. Post-ERBT recurrence remained strongly influenced by prior recurrence history, highlighting the importance of risk-adapted postoperative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.